Article Details

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ...

Retrieved on: 2021-12-12 05:01:14

Tags for this article:

Click the tags to see associated articles and topics

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA .... View article details on HISWAI: https://www.prnewswire.com/news-releases/new-data-from-phase-3-glow-study-show-fixed-duration-treatment-with-imbruvica-ibrutinib-plus-venetoclax-demonstrated-deeper-and-sustained-undetectable-minimal-residual-disease-outcomes-in-first-line-chronic-lymphocytic-leukemia-301442621.html

Excerpt

Data from the primary analysis from both the fixed-duration and MRD-guided cohorts were previously reported.4,5 Patients with high-risk disease ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up